A consortium led by Asia healthcare-focused private equity firm CBC Group has agreed to acquire a 46.9% interest in Hugel, a South Korean manufacturer of botox and other health-related pharmaceuticals, for KRW1.7 trillion ($1.5 billion).
Having agreed to provide a succession solution to the founder of Korean furniture retailer and interior designer Hanssem, IMM Private Equity wants to harness growth through demographics and differentiation
Qiming Venture Partners is mobilizing its newly launched public equities unit – and $500 million fund – to participate as an anchor investor in Hong Kong IPOs by Chinese healthcare companies.
An employee stock ownership plan introduced alongside Hillhouse Capital’s 2019 investment in Gree Electric Appliances has raised questions about enrichment and alignment
Joy Capital and Nio Capital will invest $315 million in China-based online used car dealer Uxin, throwing their support behind the company’s pivot from a marketplace to an inventory-holding retailer.
Advent International has offloaded its final 5.4% holding in Crompton Greaves’ India-listed household appliances business, ending a gradual exit after a failed takeover.
The Carlyle Group has agreed to invest up to INR31.8 billion ($439 million) in India-listed PNB Housing Finance, which would give it a majority interest in the company and trigger an open offer for an additional stake.
Beleaguered by a string of scandals and unable to turn the tide of negative publicity, the family owner of Namyang Dairy Products opted to sell to private equity. His first call was to Hahn & Company
Advantage Partners has agreed to invest about JPY7 billion ($64.6 billion) in Tokyo-listed coffeeshop and bakery chain Saint Marc.
Conservative yet contrarian, Samena Capital has carved its own path prioritizing patience, trust, and transparency. A younger generation of leadership is guiding entry into a new digital landscape
The Blackstone Group is set to lift its controlling position in India-listed IT services provider Mphasis to 75% as part of a deal worth up to $2.8 billion.
Baring Private Equity Asia has invested $100 million in Hutchison China MediTech (HutchMed), a US and London-listed drug discovery business that has two fully commercialized oncology products in China.
IMM Private Equity has agreed to sell its 40% stake in Taihan Electric Wire, a Korea-based manufacturer of high-voltage cables to Hoban Construction for KRW251.8 billion ($222 million).
Novo Tellus Capital Partners has invested S$23.6 million ($17.7 million) in Grand Venture Technology, a Singapore-listed provider of testing, assembly, and engineering services for semiconductor manufacturing.
Silver Lake has led a $2.3 billion investment in TAL Education Group, a US-listed Chinese after-school education provider, via a convertible notes issue.
MBK Partners has agreed to subscribe to $175 million in convertible bonds issued by China Auto Rental (CAR). It follows a large commitment and a take-private offer by MBK last month.
MBK Partners has agreed to invest HK$1.8 billion ($228.3 million) in Hong Kong-listed China Auto Rental (CAR), taking a 20.9% stake.
GPs like targeting banks during downturns, investing in stronger players at discount valuations and backing them to come out the other side with increased market share. Will it be more of the same with COVID-19?
PAG Asia Capital is in exclusive negotiations over a A$150 million ($109 million) investment in Regional Express Holdings (Rex), an Australian airline that emerged following the collapse of Ansett Airlines.
Seeing Korean banks trading at discounted valuations and believing in the long-term health of the industry, some private equity investors have taken the opportunity to buy in the public markets
Evergrande New Energy Vehicle (NEV), a subsidiary of Chinese real estate developer Evergrande Group, has raised HK$4 billion ($516 million) from investors including Tencent Holdings, Sequoia Capital China, Yunfeng Capital, and Didi Chuxing.
DCP Capital Partners has acquired a 9% stake in Tonghua Dongbao Pharmaceutical, a Chinese pharmaceutical company specializing in diabetes treatment, for RMB1.94 billion ($283.7 million).
I-Mab Biopharma, a private equity-backed Chinese drug developer that listed in the US as recently as January, has raised $418 million through a private placement.
The Carlyle Group has paid about $260 million for a 5% stake in Shenzhen-listed Salubris Pharmaceutical.